On October 21, 2026 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that two oral presentations and two poster presentations featuring its NeXT Personal ultrasensitive circulating tumor DNA (ctDNA) test will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026, taking place October 23-27 in Madrid, Spain. Highlights include a late-breaking oral presentation of NeXT Personal data for the C-POST Phase 3 study in cutaneous squamous cell carcinoma, as well as a Rapid Oral presentation from B-STRONGER-1, a prospective, multicenter study evaluating NeXT Personal for detecting molecular residual disease in patients with early-stage triple-negative breast cancer receiving neoadjuvant therapy.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"B-STRONGER-1 builds on our earlier work in triple-negative breast cancer demonstrating the use of ultrasensitive MRD testing for monitoring neoadjuvant therapy response," said Richard Chen, MD, President and Chief Medical Officer of Personalis. "We are also excited to see NeXT Personal data presented from biopharma in new indications like cutaneous squamous cell carcinoma as we continue to expand evidence around NeXT Personal for a broad range of solid tumors."
Presentation Schedule
Late-Breaking Oral Presentation
Title: C-POST phase 3 trial of adjuvant (adj) cemiplimab (cemi) vs placebo (pbo) for high-risk cutaneous squamous cell carcinoma (CSCC): Updated overall survival (OS) and outcomes from circulating tumour DNA (ctDNA) analyses
Presenter: Danny Rischin, M.D.; Peter MacCallum Cancer Centre
Abstract: LBA59 | Session: Rapid Oral – Melanoma and Other Skin Tumours
Time: Sun, 10/25/2026, 10:42 – 10:47 CET
Location: Granada Auditorium – Hall 4
Rapid Oral Presentation – B-STRONGER-1
Title: Ultrasensitive monitoring of early ctDNA dynamics during neoadjuvant treatment in early-stage triple-negative breast cancer: Pre-interim results from the B-STRONGER-I study
Presenter: Carlos Barcenas, M.D.; The University of Texas MD Anderson Cancer Center
Abstract: 540RO | Session: Rapid Oral – Breast Cancer, Early Stage
Time: Fri, 10/23/2026, 16:42 – 16:47 CEST
Location: Alicante Auditorium – Hall 6
Poster Presentations
Title: Ultrasensitive ctDNA kinetics predict early immunotherapy response and complement radiographic assessment in advanced cancer. (UC San Diego). Abstract # 4280P | Session: Translational Research and Biomarkers | Time: Fri, 10/23/2026, 15:15 – 16:00 CEST | Location: Poster Area – Hall 5
Title: Circulating tumour DNA (ctDNA), cancer antigen 125 (CA125) and human epididymis protein 4 (HE4) associate with survival outcomes in patients with platinum- resistant ovarian cancer (PROC) treated with ubamatamab (uba). (Yonsei University Health System). Abstract # 1957P | Session: Investigational Immunotherapy | Time: Sat, 10/24/2026, 12:00 – 12:45 CEST | Location: Poster Area – Hall 5
(Press release, Personalis, OCT 21, 2026, View Source [SID1234673654])